Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab plus topical corticosteroids in adults with severe atopic dermatitis unsuitable for cyclosporine A
2015-002653-35Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Sep 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dupilumab in atopic dermatitis (AD) (3 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: EASI 75 at week 16. Started Sep 2015; status: completed.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2015-002653-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002653-35.